Moderna Stock Soars 177% as Cancer Vaccine Delivers a Landmark Phase 3 Win

Overview

Moderna's stock experienced its largest single-day increase ever, surging 177.2% to close at $174.38 following the announcement of positive Phase 3 results for a personalized mRNA cancer vaccine in high-risk melanoma patients. This remarkable rally added approximately $44 billion to Moderna's market capitalization, bringing it to around $69.4 billion. Merck, which partnered with Moderna on this project, also saw its shares rise by 12.6% to a record $152.20.

Key Takeaways

• The personalized cancer vaccine trial met both primary endpoints.
• Significant improvements in recurrence-free and distant metastasis-free survival were observed compared to Keytruda alone.
• Moderna's stock rose 177%, while Merck's stock increased by 12.6%.
• Detailed efficacy figures from the Phase 3 trial are pending.

Phase 3 Trial Results

The INTerpath-001 study evaluated the efficacy of intismeran autogene (previously known as V940 or mRNA-4157) in combination with Merck’s Keytruda. This treatment was administered post-surgery to patients with completely resected Stage IIB to IV melanoma who were at high risk of recurrence. The combination therapy demonstrated statistically significant improvements in both recurrence-free survival (how long patients live without cancer returning) and distant metastasis-free survival (whether the disease spreads) compared to Keytruda alone.

Importantly, no unexpected safety issues were reported, and the safety profile was consistent with prior studies. However, specific details such as hazard ratios and overall survival rates have not yet been disclosed. The complete findings are expected to be presented at an international medical conference, and discussions regarding regulatory submissions are planned.

Mechanism of Action

Intismeran is a therapeutic cancer vaccine, which differs from preventive vaccines. It involves analyzing the genetic material from a patient's tumor to identify unique mutations. Moderna then creates a customized dose containing synthetic mRNA that instructs the immune system to recognize and attack cells with those mutations. Keytruda works by blocking the PD-1 pathway, which cancer cells exploit to evade the immune response. The combination aims to enhance the immune system's ability to detect and combat cancer cells.

Previous Results and Market Impact

Prior Phase 2 results had already established intismeran as one of Moderna's most valuable assets outside of COVID-related products, showing a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death compared to Keytruda alone. Meeting the Phase 3 endpoints provides stronger evidence that the benefits observed in earlier studies were not merely statistical anomalies.

The announcement triggered a short squeeze, as approximately 13.7% of Moderna's shares were sold short prior to the news. This contributed to the stock's dramatic rise, which has now increased by about 445% in 2026, although it remains below its peak of nearly $484 in August 2021.

Future Outlook

The success of this trial could position Moderna to expand its business beyond respiratory vaccines, with ongoing studies into other tumor types, including lung, kidney, and bladder cancers. However, the market will be closely watching for the full Phase 3 dataset to assess the treatment's clinical and commercial viability. Analysts suggest a potential U.S. approval could occur in 2027, but this remains speculative. The next challenge for Moderna will be to translate this scientific breakthrough into a scalable and profitable oncology franchise.